Hyundai Bioscience
Financials
Valuation Metrics
Hyundai Bioscience's Market Cap is ₩6514B. At end of 2025 it was ₩4792B. Ranked #399 of 2,421 in KR market (top 16%), #137 of 1,640 on KOSDAQ (top 8%), #9 of 57 in Household & Personal Products (top 16%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 651.41B KRW | KR#399/2,421 Sec#9/57 |
| Revenue | 3.32B KRW | KR#2,365/2,421 Sec#57/57 |
| Net Income | -28.61B KRW | KR—/2,421 Sec—/57 |
| Total Assets | 131.31B KRW | KR#1,595/2,421 Sec#31/57 |
| Net Assets | 103.31B KRW | KR#1,391/2,421 Sec#28/57 |
| Employees | 55 | KR#2,014/2,421 Sec#50/57 |
| Value | ||
| P/B | 6.31x | KR#2,289/2,421 Sec#54/57 |
| P/S | 196.16x | KR#2,402/2,421 Sec#57/57 |
| FCF Yield | -2.68% | KR—/2,421 Sec—/57 |
| Profitability | ||
| ROE | -27.69% | KR#2,161/2,421 Sec#52/57 |
| ROA | -21.79% | KR#2,258/2,421 Sec#54/57 |
| Op. Margin | -580.09% | KR#2,372/2,421 Sec#57/57 |
| Revenue Growth | 77.96% | KR#125/2,421 Sec#3/57 |
| Financial Health | ||
| Debt Ratio | 27.10% | KR#526/2,421 Sec#15/57 |
| Total Debt | 21.32B KRW | KR#1,356/2,421 Sec#28/57 |
| FCF | -17.47B KRW | KR#1,861/2,421 Sec#46/57 |
| Cash | 17.08B KRW | KR#1,346/2,421 Sec#25/57 |
| Current Ratio | 2.36x | KR#732/2,421 Sec#22/57 |
| Performance | ||
| 1Y Return | 20.32% | KR#436/2,421 Sec#9/57 |
| 1M Return | -5.73% | KR#1,852/2,421 Sec#43/57 |
| From 52W High | -68.60% | KR#2,157/2,421 Sec#51/57 |
| 1Y MDD | -73.65% | KR#2,129/2,421 Sec#50/57 |
| Trading | ||
| Volume | 698,938 shares | KR#180/2,421 Sec#3/57 |
| Trading Value | 4.73B KRW | KR#375/2,421 Sec#10/57 |
| Foreign Own. | 6.24% | KR#709/2,421 Sec#14/57 |
| Per Share | ||
| EPS | -296 KRW | KR—/2,421 Sec—/57 |
| BPS | 1,070 KRW | KR#2,290/2,421 Sec#55/57 |
Company Info
Spun off from Hyundai Electronics in 2000, this bio pharmaceutical and cosmeceutical company was listed on KOSDAQ in 2002 and renamed Hyundai Bioscience in 2018. It is developing the broad-spectrum antiviral treatment CP-COV03 and anticancer drugs Polytaxel and Penicillium, while expanding its domestic and international markets with high-functional cosmetics Vitabrid C12 (exported to Japan) and Dr.BRID C. The company is securing new drug development pipelines in cooperation with C&Pharm and pursuing commercialization of clinical results through exchanges with international organizations. Hyundai Bio is headquartered in Gimcheon-si, Gyeongsangbuk-do.